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A NEW MEASURE FOR ASSESSING HEALTH-RELATED
QUALITY OF LIFE (HRQOL) IN PATIENTS WITH ADVANCED
COLORECTAL CANCER (ACC): “CCRA-QOL”
Perulero N1, Badia X1, Marfá X2, Guallar JL2
1Health Outcomes Research Europe, Barcelona, Spain; 2Sanoﬁ—
Aventis, S.A.U, Barcelona, Spain
OBJECTIVE: To develop an instrument to measure HRQoL in
patients with advanced colorectal cancer (ACC) given that there
are no speciﬁcally designed for this purpose. METHODS: In
order to deﬁne the main dimensions the questionnaire should
cover, a scientiﬁc literature review, a speciﬁc interview and a
focus group with seven experts (four oncologists, two nurses and
one psychologist) were performed. Later, an in depth semistruc-
tured interview was conducted in eight patients with ACC to
evaluate the impact of disease symptoms and treatment in
HRQoL. From the content of the interviews a sample of items
were identiﬁed. Each item was subsequently rated by the same
panel of experts, according to clarity, frequency and importance
to patients with ACC (qualitative reduction). Remaining items
were edited in the questionnaire form in order to be self-admin-
istrated to a sample of 35 patients in a cross-sectional study.
After that, a factor analysis and a Rasch analysis were performed
to obtain the ﬁnal questionnaire. RESULTS: Twelve dimensions
were identiﬁed by experts. From the qualitative analysis, a ques-
tionnaire with 27 item was obtained, 4 items were only applic-
able to a speciﬁc subset of patients (items analysed
independently). Factor analysis from the remaining 23 items
identiﬁed 4 dimensions explaining 56.14% of total variance. In
each dimension the Rasch analysis was used to exclude those
items with inadequate adjustment (INFIT > 1.30) or redundant
with other items in the measurement scale, obtaining in total 16
items. The ﬁnal questionnaire includes 16 items with a good
internal consistency (Cronbach’s alpha = 0.81) and 4 additional
items that have to be analysed separately. CONCLUSION: A
new questionnaire was elaborated to measure HRQoL in
patients with ACC with a good reliability. Psychometric proper-
ties are currently being tested in conditions of real clinical 
practice.
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MODELLING THE EFFECT OF A NOVEL THERAPEUTIC AGENT
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OBJECTIVES: To estimate the effect of Bortezomib on utility
values in multiple myeloma patients. METHODS: A Phase III
trial (APEX) compared Bortezomib with High Dose Dexam-
ethasone. Utility scores (EuroQol-5D) were collected together
with a comprehensive range of clinical and serological outcomes.
Changes in utility scores were analysed separately for survivors
and non-survivors using non-parametric regression methods. A
maximum likelihood method that adjusts for the latent, under-
lying risk of death as a utility-driver was employed to take
account of unobservable effects of declining health on utility
scores. RESULTS: Data for 655 out of a total of 669 patients in
APEX were included in the analysis, including 129 patients for
whom information was available on time to death. Mean utility
scores before progression were similar between Responders
(0.65) and Non-responders (0.61; mean diff. 0.045, 95% CI -
0.01, 0.10); the respective estimates for the after-progression
phase (0.67 vs. 0.58) had a mean difference of 0.10 (95% CI -
0.00, 0.19). No differences were found between treatment
groups. A steep decline in utility over time, following a stable
period, began approximately 100 days before death. Estimates
from a two-step regression model of utility scores are consistent
with informative censoring or sample selection bias in the esti-
mating sample; adjusting for such bias reduced the estimated
post-progression difference between responders and non-respon-
ders. CONCLUSIONS: The last days of life in patients with mul-
tiple myeloma are associated with a steep decline in health
related quality of life. Evaluations of utility outcomes conducted
alongside clinical trials of salvage therapies in hematology and
cancer are likely to require adjustment for the unavailability of
representative samples for assessment as a result of early trial ter-
mination. We propose an approach commonly used in other
ﬁelds to deal with this issue and discuss its advantages and lim-
itations.
PCN43
CRITICAL APPRAISAL OF SCIENTIFIC POSTERS COMPARING
ANEMIA TREATMENTS IN CANCER PATIENTS: APPLYING
ISPOR TASK FORCE GUIDELINES ON METHODOLOGICAL
QUALITY OF RETROSPECTIVE STUDIES
Demarteau N, Moeremans K,Annemans L
IMS Health, Brussels, Belgium
OBJECTIVE: Lack of space may prevent research posters from
fully disclosing methodological details. Nevertheless they are
increasingly used as scientiﬁc evidence in communications with
health care professionals and as references in review articles,
although they are not subject to extensive peer-review. The objec-
tive of this study was to assess the methodological quality of
posters with results from retrospective database studies on the
use of erythropoiesis-stimulating proteins [epoetin alfa (Eprex®),
epoetin beta (NeoRecormon®), or darbepoetin alfa (Aranesp®)]
in the management of anemia in cancer patients. METHODS:
We evaluated the quality of research posters in anemia, presented
at European congresses since 2004 by using the methodological
criteria published by the ISPOR Task Force on Retrospective
Database. Two reviewers assessed all posters independently. In
total 21 criteria were applied: 3 on data sources, 3 on research
design, 8 on study population, 5 on statistical analyses and 2 on
conclusions. RESULTS: Four posters were assessed (Persson,
ISPOR 2004; Reichardt, ÖGHO 2004; Malonne, BHS 2005;
Pujade-Lauraine, ECCO 2004). Three presented a retrospective
cost-minimization analysis and one a retrospective efﬁcacy eval-
uation. Overall, the quality of the analyses was poor to very poor
satisfying from 14% to 38% of the criteria. Very low scores were
observed regarding the quality of the data sources and the
research design (scoring 0/3 each in the 3 cost-minimization
studies). Key elements such as selection bias were not considered.
Cost data were mostly limited to speciﬁc categories, such as drug
costs, without including other costs associated with the condi-
tion and its treatment. CONCLUSIONS: The ISPOR guidelines
for the evaluation of retrospective analyses are a useful tool for
quality assessment of scientiﬁc posters. When assessed against
these guidelines, all posters revealed serious methodological
shortcomings. These ﬁndings caution against the use of posters
without appropriate assessment of their methodological quality.
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HEALTH RELATED QUALITY OF LIFE EVALUATIONS IN
PROSTATE CANCER: WHO’S BEING STUDIED?
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OBJECTIVES: The issue of health-related quality-of-life
(HRQOL) of prostate cancer patients has gained prominence.
